Analysts Set Guardant Health, Inc. (NASDAQ:GH) PT at $36.91

Guardant Health, Inc. (NASDAQ:GH) has been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $36.91.

Several analysts have recently issued reports on the company. Stephens reissued an “overweight” rating and set a $44.00 target price on shares of Guardant Health in a report on Friday, May 24th. Jefferies Financial Group started coverage on shares of Guardant Health in a report on Monday, June 3rd. They issued a “buy” rating and a $32.00 target price on the stock. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Craig Hallum assumed coverage on Guardant Health in a research report on Wednesday, April 24th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Canaccord Genuity Group raised their price objective on Guardant Health from $30.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, June 4th.

Guardant Health Price Performance

GH stock opened at $29.39 on Monday. The stock has a 50-day moving average price of $24.47 and a two-hundred day moving average price of $22.95. Guardant Health has a 1 year low of $15.81 and a 1 year high of $41.06. The stock has a market cap of $3.60 billion, a PE ratio of -7.50 and a beta of 1.15. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.94). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The business had revenue of $168.49 million during the quarter, compared to the consensus estimate of $150.51 million. Equities analysts forecast that Guardant Health will post -3.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Several institutional investors have recently added to or reduced their stakes in GH. Vanguard Group Inc. boosted its position in shares of Guardant Health by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 11,436,026 shares of the company’s stock valued at $235,925,000 after acquiring an additional 305,372 shares during the last quarter. Baillie Gifford & Co. increased its holdings in shares of Guardant Health by 0.9% in the 1st quarter. Baillie Gifford & Co. now owns 6,232,104 shares of the company’s stock worth $128,568,000 after buying an additional 53,292 shares during the last quarter. Capital International Investors raised its position in shares of Guardant Health by 36.7% during the 4th quarter. Capital International Investors now owns 4,001,803 shares of the company’s stock valued at $108,249,000 after buying an additional 1,074,452 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Guardant Health by 8.3% during the 4th quarter. Eventide Asset Management LLC now owns 3,888,146 shares of the company’s stock worth $105,174,000 after acquiring an additional 298,616 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Guardant Health by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,232,117 shares of the company’s stock worth $33,329,000 after acquiring an additional 20,618 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.